Background

Alzheimer's disease (AD), a progressive neurodegenerative disease, is more common disease of dementia among the elderly by multiple factors and presents enormous challenges in terms of diagnosis and treatment. Kaixin San (KXS), is a classic prescription for the treatment of memory decline and applied for AD nowadays. However, the quality-markers of KXS for the treatment of AD remain unclear.

Purpose

To investigate the effects and potential quality-markers of KXS against an APP/PS1 transgenic mouse model of AD.

Methods

Two month old APP/PS1 transgenic model mice of AD were orally given KXS for 10 month to intervene. Through the novel object recognition (NOR), the classic Morris water maze (MWM), immunohistochemistry detection of Aβ1-42, Hematoxylin-eosin staining (HE), blood metabolic profiling evaluated the therapeutic effect of KXS on AD. PCMS software was applied to analysis correlations between biomarkers and serum constituents and became a powerful tool for excavating effective material basis. Behavior, histopathology and Chinmedomics were applied for assessing the efficacy and discovering potential quality-markers.

Results

The result of MWM showed oral KXS could shorten the escape latency and increased the times of crossing the platform. The result of NOR showed oral KXS increased discrimination index (DI). Though the histopathology, KXS reduced the necrosis of neuron in brain tissue and the deposition of Aβ1-42. Chinmedomics strategy was used to analyze the biomarkers and blood components. KXS called back 20 biomarkers of AD. The effective material basis of KXS was ginsenoside Rf, ginsenoside F1, 20-O-glucopyranosyl ginsenoside Rf, dehydropachymic acid and E-3, 4, 5-trimethoxycinnamic acid.

Conclusion

This study demonstrate that KXS significantly improved cognitive function of transgenic mice of AD, repaired the damage caused by Aβ, regulated amino acid metabolism and lipid metabolism abnormalities and determined the effective material basis of KXS treating AD. Clarifying the quality-markers of KXS can establish scientific quality standard to reflect the safety and effectiveness of Traditional Chinese Medicine (TCM).

中文翻译：

---

运用淫羊dom分析方法快速发现开新山的质量标志物

背景

阿尔茨海默氏病（AD）是一种进行性神经退行性疾病，在多种因素中，它是老年人痴呆症中较常见的疾病，并且在诊断和治疗方面提出了巨大挑战。开新散（KXS）是治疗记忆力减退的经典处方，如今已用于AD。但是，尚不清楚KXS用于治疗AD的质量指标。

目的

调查的影响和潜在的质量标志物对AD的APP / PS1转基因小鼠模型的影响。

方法

对两个月大的AD的APP / PS1转基因模型小鼠口服KXS干预10个月。通过新颖的物体识别（NOR），经典的莫里斯水迷宫（MWM），Aβ1-42的免疫组织化学检测，苏木精-伊红染色（HE），血液代谢分析，评估了KXS对AD的治疗效果。PCMS软件被用于分析生物标志物与血清成分之间的相关性，成为挖掘有效物质基础的有力工具。行为，组织病理学和Chinmedomics被用于评估疗效和发现潜在的质量标志物。

结果

MWM的结果表明，口服KXS可以缩短逃生潜伏期，并增加穿越平台的时间。NOR的结果显示口服KXS的辨别指数（DI）升高。通过组织病理学，KXS减少了脑组织中神经元的坏死和Aβ1-42的沉积。Chinmedomics策略用于分析生物标志物和血液成分。KXS召回了20种AD的生物标志物。KXS的有效物质基础是人参皂苷Rf，人参皂苷F1、20-O-吡喃葡萄糖基人参皂苷Rf，脱氢叶酸和E-3、4、5-三甲氧基肉桂酸。

结论

这项研究表明，KXS显着改善了转基因AD小鼠的认知功能，修复了Aβ引起的损伤，调节了氨基酸代谢和脂质代谢异常，并确定了KXS治疗AD的有效物质基础。澄清KXS的质量标记可以建立科学的质量标准，以反映中药（TCM）的安全性和有效性。